ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last2,041 to 2,060 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Placebo Bid + Symbicort 'as Needed' (Experimental) vs Pulmicort Bid + Terbutaline 'as Needed' (Active Comparator): deaths from any cause1 of 2,089

1 of 2,087

-0.0 points

-0.2 to 0.2

4,176NCT02224157

A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma

Placebo Bid + Symbicort 'as Needed' (Experimental) vs Pulmicort Bid + Terbutaline 'as Needed' (Active Comparator): Number of Participants With Study Specific Asthma Related Discontinuation0 of 2,089

4 of 2,087

-0.2 points

-0.5 to 0.0

4,176NCT02224157

A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma

Placebo Bid + Symbicort 'as Needed' (Experimental) vs Pulmicort Bid + Terbutaline 'as Needed' (Active Comparator): Number of Participants Experiencing at Least One Severe Asthma Exacerbation177 of 2,089

184 of 2,087

-0.3 points

-2.1 to 1.4

4,176NCT02224157

A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma

Placebo Bid + Symbicort 'as Needed' (Experimental) vs Pulmicort Bid + Terbutaline 'as Needed' (Active Comparator): serious adverse events66 of 2,089

73 of 2,087

-0.3 points

-1.4 to 0.8

4,176NCT02224157

A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma

Colchicine vs Placebo: Number of Participants Who Died or Were Hospitalized Due to COVID-19 Infection in the 30 Days Following Randomization in the Subgroup of Patients With PCR-confirmed COVID-19.96 of 2,075

126 of 2,084

-1.4 points

-2.8 to -0.1

4,159NCT04322682

Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)

Receives OUD-CDS vs Does Not Receive the OUD-CDS: Number of Patients With OUD Diagnosis36 of 2,079

24 of 2,074

0.6 points

-0.2 to 1.3

4,153NCT04198428

Clinical Decision Support for Opioid Use Disorders in Medical Settings (COMPUTE 2.0)

All TNFi Initiators Combination vs Tofacitinib Initiators Monotherapy: Number of Participants With mACR20 at 6 Months for Tofacitinib Monotherapy vs TNFi Combination With MTX1,224 of 4,013

28 of 135

9.8 points

2.0 to 15.9

4,148NCT05576051

To Estimate the Efficacy of Treatment With TNFi as Monotherapy or Combination Therapy With MTX and Compare and Contrast Efficacy With Tofacitinib as Monotherapy and Combination Therapy in a Real World Setting.

IRBESARTAN vs PLACEBO: serious adverse events1,146 of 2,064

1,155 of 2,062

-0.5 points

-3.5 to 2.5

4,126NCT00095238

Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve)

Ivermectin Mass Drug Administration vs Placebo Mass Administration: deaths from any cause6 of 2,191

3 of 1,933

0.1 points

-0.2 to 0.5

4,124NCT03967054

Repeat Ivermectin Mass Drug Administrations for MALaria Control II

Ivermectin Mass Drug Administration vs Placebo Mass Administration: serious adverse events8 of 2,191

6 of 1,933

0.1 points

-0.4 to 0.4

4,124NCT03967054

Repeat Ivermectin Mass Drug Administrations for MALaria Control II

BCG-vaccine vs Control Children: DTaP-IPV-Hib Vaccination Coverage at 12 Months of Age1,175 of 2,018

1,207 of 2,097

0.7 points

-2.3 to 3.7

4,115NCT01694108

Bacille Calmette Guérin Immunisation at Birth and Childhood Morbidity in Danish Children.

VLA1553 vs Placebo: Serious Adverse Event46 of 3,082

8 of 1,033

0.7 points

-0.1 to 1.3

4,115NCT04546724

Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults

VLA1553 vs Placebo: Related Adverse Event of Special Interest9 of 3,082

1 of 1,033

0.2 points

-0.3 to 0.5

4,115NCT04546724

Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults

VLA1553 vs Placebo: Related Serious Adverse Event2 of 3,082

0 of 1,033

0.1 points

-0.3 to 0.2

4,115NCT04546724

Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults

VLA1553 vs Placebo: Unsolicited AEs687 of 3,082

138 of 1,033

8.9 points

6.3 to 11.4

4,115NCT04546724

Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults

VLA1553 vs Placebo: Related Adverse Events1,575 of 3,082

322 of 1,033

19.9 points

16.5 to 23.2

4,115NCT04546724

Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults

VLA1553 vs Placebo: Adverse Event of Special Interest10 of 3,082

1 of 1,033

0.2 points

-0.2 to 0.5

4,115NCT04546724

Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults

VLA1553 vs Placebo: deaths from any cause2 of 3,082

1 of 1,033

-0.0 points

-0.5 to 0.2

4,115NCT04546724

Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults

VLA1553 vs Placebo: serious adverse events46 of 3,082

8 of 1,033

0.7 points

-0.1 to 1.3

4,115NCT04546724

Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults

rIL-2 vs No rIL-2: Grade 4 Signs and Symptoms466 of 2,071

383 of 2,040

3.7 points

1.3 to 6.2

4,111NCT00004978

An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=103"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=103

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02224157-deaths",
        "title": "Placebo Bid + Symbicort 'as Needed' (Experimental) vs Pulmicort Bid + Terbutaline 'as Needed' (Active Comparator): deaths from any cause",
        "summary": "1 of 2089 against 1 of 2087; risk difference -0.0 points, 95% interval -0.2 to 0.2; NCT02224157, A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma",
        "record": "/library/comparisons/NCT02224157-deaths",
        "nct_id": "NCT02224157",
        "kind": "deaths",
        "participants": 4176,
        "risk_difference": {
          "value": -4.5874263689398443e-7,
          "lower": -0.0022651163914397896,
          "upper": 0.0022621671366750942
        },
        "group_1": "1 of 2,089",
        "group_2": "1 of 2,087",
        "difference": "-0.0 points",
        "interval": "-0.2 to 0.2",
        "trial_title": "A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma"
      },
      {
        "id": "NCT02224157-f8ac8bc7",
        "title": "Placebo Bid + Symbicort 'as Needed' (Experimental) vs Pulmicort Bid + Terbutaline 'as Needed' (Active Comparator): Number of Participants With Study Specific Asthma Related Discontinuation",
        "summary": "0 of 2089 against 4 of 2087; risk difference -0.2 points, 95% interval -0.5 to 0.0; NCT02224157, A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma",
        "record": "/library/comparisons/NCT02224157-f8ac8bc7",
        "nct_id": "NCT02224157",
        "kind": "outcome",
        "participants": 4176,
        "risk_difference": {
          "value": -0.0019166267369429804,
          "lower": -0.00491790626171383,
          "upper": 0.00026063936880732844
        },
        "group_1": "0 of 2,089",
        "group_2": "4 of 2,087",
        "difference": "-0.2 points",
        "interval": "-0.5 to 0.0",
        "trial_title": "A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=104",
  "request_id": "v5qRvCrTxZggv7BH"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?